You are spot on IMO, drpat. The trial went well from all reports, and the patent(s) should hold strong. The major pharmas, e.g. Novartis 9Sandoz) and others all settled and agreed to hold off until 2026, as they knew they had virtually no chance of prevailing in the litigation.
Drop in PPS presents good opportunity to average down in overall PPS, IMO.